10-Q: Biomerica Reports Q1 Net Income Amidst Sales Decline

Biomerica, Inc. reported a net income of $2,000 for Q1 2026, a significant improvement from a loss in the prior year, primarily driven by a one-time Employee Retention Credit refund, despite a 24% drop in net sales.

Summary

• Net sales for the three months ended August 31, 2025, decreased by $427,000, or 24%, to $1,380,000 compared to $1,807,000 in the same period of 2024.
• Gross profit increased by 46.7% to $424,000 (30.7% of net sales) for Q1 2026, up from $289,000 (16% of net sales) in Q1 2025, driven by lower contract manufacturing costs and improved production efficiency.
• The company reported a net income of $2,000 for the three months ended August 31, 2025, a substantial improvement from a net loss of $1,316,000 in the prior year period.
• Other income included a $1,100,000 cash refund from the IRS related to the Employee Retention Credit (ERC), a one-time, non-recurring item.
• Cash used in operating activities significantly decreased to $268,000 for Q1 2026, compared to $1,344,000 for Q1 2025.
• Cash and cash equivalents increased to $3,053,000 as of August 31, 2025, from $2,399,000 as of May 31, 2025.
• Working capital improved to $4,206,000 as of August 31, 2025, from $3,135,000 as of May 31, 2025.
• The company raised $912,000 in net proceeds from an At-The-Market (ATM) offering during the quarter, selling 258,569 shares of common stock.
• Management has identified substantial doubt about the company's ability to continue as a going concern for the next twelve months, citing insufficient cash to meet operating requirements and strategic growth objectives.
• Cost-cutting measures, including a Reduction in Force (RIF) in July 2024, contributed to reduced selling, general, administrative, and research and development expenses.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant 24% decline in net sales, continued 'going concern' doubt, and slower-than-expected product launches. While the company reported a net income, it was primarily due to a one-time, non-recurring Employee Retention Credit refund, masking underlying operational challenges. The capital raise provides temporary liquidity but doesn't resolve fundamental issues.

Positives

• Achieved a net income of $2,000 for the quarter, a significant turnaround from a $1,316,000 net loss in the prior year, largely due to a one-time $1,100,000 Employee Retention Credit refund.
• Gross profit increased by 46.7% to $424,000, with gross margin improving from 16% to 30.7% of net sales, reflecting lower contract manufacturing costs and improved production efficiency.
• Operating expenses decreased by 6.9% year-over-year, with selling, general, and administrative expenses down 2% and research and development expenses down 29%, primarily due to cost-cutting measures and a Reduction in Force.
• Cash used in operating activities significantly reduced to $268,000 from $1,344,000 in the prior year period, indicating improved operational cash management.
• Successfully raised $912,000 in net proceeds through an At-The-Market (ATM) offering, enhancing liquidity.
• Cash and cash equivalents increased to $3,053,000, and working capital improved to $4,206,000 as of August 31, 2025.
• Received FDA clearance for hp+detect, a diagnostic test for Helicobacter pylori, in December 2023, and is actively promoting it to laboratories.
• Positive feedback from GI physician groups on the inFoods IBS product, with efforts underway to expand the network and explore distribution partnerships.

Negatives

• Net sales decreased by 24% to $1,380,000 for the quarter, primarily due to reduced retail market activity, lower international over-the-counter (OTC) sales (partially due to tariff impacts), and decreased demand under certain contract manufacturing agreements.
• The positive net income was largely attributable to a one-time $1,100,000 Employee Retention Credit refund; without this, the company would have reported a significant net loss.
• Management has identified substantial doubt about the company's ability to continue as a going concern for the next twelve months, indicating insufficient current cash to meet operating and strategic needs.
• Product launches for key products, inFoods IBS and hp+detect, have been slower-than-expected.
• The company continues to incur recurring operating losses and negative cash flows from operations, with an accumulated deficit of approximately $53,200,000 as of August 31, 2025.
• One key customer in Asia accounted for 48% of net sales for the three months ended August 31, 2025, indicating significant customer concentration risk.

Risks

• Ability to raise additional capital and continue as a going concern due to recurring operating losses and negative cash flows.
• Accuracy of estimates regarding expenses, future revenue, capital requirements, and needs for additional financing.
• Scope of protection for intellectual property rights covering products and technology.
• Ability to compete in the industry against competitors with significantly greater financial, technical, and marketing resources.
• Ability to obtain and maintain government or regulatory certification in countries and regions where products are sold.
• Ability to maintain relations with key distributors, given significant customer concentration.
• Impact of global economic and political developments, including rising inflation, interest rates, capital market disruptions, and economic slowdowns, on research and development efforts and access to capital markets.
• Risks related to third parties asserting intellectual property infringement claims.
• Impact of numerous laws and regulations and compliance with these laws.
• Risks related to product recalls, claims of liability, and harm to patients or users of products.
• Ability to retain key personnel and to identify, hire, and retain additional qualified professionals.
• Uncertainty regarding the success and timing of obtaining U.S. government payment or reimbursement (Medicare) for the inFoods IBS product, which is crucial for dramatically increasing revenues.

Future Outlook

Management believes current cash and cash equivalents are insufficient to meet operating cash requirements and strategic growth objectives for the next twelve months, raising substantial doubt about the company's ability to continue as a going concern. The company is actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, seek additional financing through debt or equity, and explore other strategic alternatives. Future viability depends on the successful execution of strategic plans, securing additional near-term financing, and achieving profitable operations. The company expects dramatic revenue increases from the inFoods IBS product if U.S. government payment or reimbursement is attained.

Management Comments

• Management has analyzed our cash flow requirements through November 2026 and beyond. Based on this analysis, we believe our current cash and cash equivalents are insufficient to meet our operating cash requirements and strategic growth objectives for the next twelve months.
• To address our capital needs and sustain operations beyond the next year, we are actively pursuing strategies to increase sales, reduce expenses, sell non-core assets, seek additional financing through debt or equity, and seek other strategic alternatives.
• While we are committed to these plans, there is no assurance that these efforts will be successful or sufficient to meet our capital requirements. These factors raise substantial doubt about our ability to continue as a going concern.
• Our future viability depends on the successful execution of our strategic plans, securing additional near-term financing, and achieving profitable operations.
• Due to the slower-than-expected launch of our key products, inFoods IBS and hp+detect, we have initiated significant cost-cutting measures to extend our cash runway and work towards increasing revenues to cover overhead costs.
• We are actively exploring strategic opportunities to enhance and create shareholder value.

Industry Context

Biomerica operates in the biomedical technology sector, focusing on diagnostic and therapeutic products, particularly for gastrointestinal diseases like IBS and H. pylori detection. The industry is characterized by ongoing technological advancements enabling point-of-care and home testing, alongside stringent regulatory requirements (FDA, CE Mark). The company's strategy to develop diagnostic-guided therapy (DGT) products aligns with a trend towards personalized medicine and reducing healthcare costs. However, the slower-than-expected commercialization of new products like inFoods IBS and hp+detect, coupled with a decline in overall sales, suggests challenges in market penetration or competitive pressures. The focus on securing reimbursement for inFoods IBS highlights the critical role of payer coverage in the U.S. diagnostic market. Global economic conditions, trade policies, and supply chain dynamics continue to be relevant factors impacting the industry.

Comparison to Industry Standards

• NA

Management Changes

Legal Proceedings

• No legal proceedings were pending as of August 31, 2025. Management believes future legal matters will not have a material adverse effect on the consolidated financial position, results of operations, or cash flows.

Related Party Transactions

• The company has an investment of approximately $165,000 in a privately held Polish distributor, owning approximately 6% of the entity. This is accounted for as a Cost Method Holding.

Stakeholder Impact

• **Shareholders:** Face significant risk due to the 'going concern' doubt and reliance on a one-time credit for profitability. Dilution from the ATM offering has occurred, and further capital raises are anticipated. The stock price may be negatively impacted by the sales decline and operational challenges.
• **Employees:** Affected by cost-cutting measures, including a Reduction in Force (RIF) implemented in July 2024, which reduced salaries and wages.
• **Customers:** May experience continued volatility in product availability or support if operational challenges persist, particularly with slower-than-expected product launches. However, increased demand for inFoods IBS and new product offerings like hp+detect could benefit certain customer segments.
• **Suppliers:** The company's efforts to diversify suppliers and implement alternative sourcing strategies could impact existing vendor relationships, though no single vendor accounted for more than 10% of raw material purchases in the current quarter.
• **Creditors:** The 'going concern' warning and need for additional financing could raise concerns about the company's ability to meet future obligations, potentially impacting credit terms or access to debt markets.

Next Steps

• Expand the network of GI physician practices for inFoods IBS and explore opportunities in other medical specialties.
• Evaluate distribution, partnership, and licensing opportunities with U.S. companies for a scalable, broad market launch of inFoods IBS.
• Apply for U.S. government payment or reimbursement (Medicare) for the inFoods IBS product, followed by applications for private payer insurance reimbursement.
• Actively promote the hp+detect diagnostic test to large end-customer laboratories for commercial adoption.
• Continue implementing cost-cutting measures to extend cash runway and increase revenues to cover overhead costs.
• Actively pursue strategies to increase sales, reduce expenses, sell non-core assets, seek additional financing through debt or equity, and explore other strategic alternatives to address capital needs.
• Monitor evolving global economic conditions, trade policies, tariffs, and supply chain dynamics, and implement contingency plans including alternative sourcing and supplier diversification.

Key Dates

Recommendation

Despite reporting a net income, the underlying operational performance is concerning. Net sales declined by a substantial 24%, and the positive net income was primarily driven by a non-recurring $1.1 million Employee Retention Credit refund, masking a continued operational loss. Management explicitly states 'substantial doubt about our ability to continue as a going concern' for the next twelve months, indicating significant financial instability. The slower-than-expected launch of key products like inFoods IBS and hp+detect further dampens growth prospects. While cost-cutting and a capital raise provide some temporary relief, the fundamental challenges of declining revenue and ongoing liquidity concerns make the stock a high-risk investment with a negative outlook for a seasoned investor.

Keywords

Biomedical Technology, Diagnostic Products, IBS, inFoods IBS, Helicobacter pylori, hp+detect, SEC Filing, 10-Q, Financial Results, Going Concern, Medical Diagnostics, Point-of-Care, Clinical Laboratories, FDA Clearance, Capital Raise, Employee Retention Credit